MicroRNA-198 (miR-198)

MicroRNA-198 (miR-198) is a small (~22 nucleotides), single-stranded, non-coding RNA molecule that belongs to the family of microRNAs—key regulators of gene expression by binding to target messenger RNAs (mRNAs) and inhibiting their translation or promoting their degradation[5][6]. MiR-198 is primarily recognized as a tumor suppressor in multiple human cancers, including pancreatic, gastric, breast, lung, liver, glioma, and others[3][4][5][6]. It can inhibit cell proliferation, migration, invasion, and induce apoptosis and cell cycle arrest in cancer cells[4][6]. Mechanistically, it acts by downregulating a range of oncogenic target genes such as MSLN, PBX-1, VCP, PTEN, FGFR1, MYC, and CDCP1, thereby modulating various tumorigenic pathways including PI3K/AKT, HGF/c-Met, and others[1][2][3][4][5][6]. Loss or downregulation of miR-198 is associated with increased tumor aggressiveness and poor clinical outcome, while restoration of miR-198 levels suppresses tumor growth and metastasis, supporting its potential role as a prognostic biomarker and a therapeutic target in oncology[3][4][5][6][1]. The therapeutic use of miR-198 mimics or modulators is being explored, but practical application faces delivery and specificity challenges[4][5].

Other names

hsa-mir-198MIR198MIRN198

Antisense oligonucleotides or miRNA mimics to restore or inhibit miR-198 function, leading to suppression of oncogene expression and reversal of tumorigenic phenotypes[3][4][5][6].